Percutaneous renal artery stenting is a common means of treating atherosclerotic renal artery stenosis. However, renal artery restenosis remains a frequent problem. The optimal treatment of restenosis has not been established and may involve percutaneous renal artery angioplasty or deployment of a second stent. Other modalities include cutting balloon angioplasty, repeat stenting with drug-eluting stents or endovascular brachytherapy. Most recently, use of polytetrafluoroethylene (PTFE)covered stents may offer a new and innovative way to treat recurrent renal artery stenosis. We describe a case in a patient who initially presented with renal insufficiency and multi-drug hypertension in the setting of severe bilateral renal artery stenosis. Her renal artery stenosis was initially successfully treated by percutaneous deployment of bilateral bare metal renal artery stents. After initial improvement of her hypertension and renal insufficiency, both parameters declined and follow-up duplex evaluation confirmed renal artery in-stent restenosis. Owing to other medical co-morbidities she was felt to be a poor surgical candidate and was subsequently treated first with bilateral cutting balloon angioplasty and second with drug-eluting stent deployment. Each procedure was associated with initial improvement of renal function and blood pressure control, which then later deteriorated with the development of further significant in-stent restenosis. It was then decided to treat the restenosis using PTFE-covered stents. At 12 months of follow-up, the blood pressure had remained stable and renal function had normalized. The covered stents remained free of any significant neointimal tissue or obstruction.
Introduction
Renal artery stenosis (RAS) is caused primarily by atherosclerotic renal disease or fibromuscular dysplasia. 1 Atherosclerotic RAS accounts for 90% of cases and its natural history is to progress with associated renal dysfunction and hypertension. 1, 2 Renal artery revascularization may prevent progressive renal failure, may lower blood pressure and prevent flash pulmonary edema or recurrent heart failure in carefully selected cases. 3, 4 Percutaneous transluminal renal angioplasty (PTRA) was initially introduced as an alternative to surgery for treating RAS. 5 Unfortunately, PTRA alone usually results in plaque recoil and subsequent restenosis. Percutaneous renal artery stenting (PTRAS), when compared with PTRA, is associated with a significant improvement in primary and secondary patency rates and reduces restenosis without an increase in the rate of complications. 6, 7 PTRAS has now replaced PTRA; however, the rate of restenosis after stenting can be as high as 23%. 8 At this time there is limited data to guide therapy for in-stent renal artery restenosis (IRAS). Prospectively studied long-term outcomes of endovascular treatment for IRAS have concluded that there is a non-significant trend towards lower restenosis with restenting of IRAS versus PTRA. 8 However, there is a lack of data examining the use of covered stents for IRAS or initial RAS.
Case report
A 78-year-old woman was admitted in February 2007 complaining of dyspnea on exertion, fullness in her head, and a sense of 'just not feeling right'. The symptoms had progressively worsened over the prior 2 months. Her past medical history was significant for multi-drug-resistant hypertension, coronary artery disease and three vessel coronary artery bypass surgery (CABG). At the time of her CABG she also underwent aortic valve replacement. She had significant peripheral artery disease with prior aortofemoral bypass surgery, a history of bilateral carotid endarterectomy, left subclavian artery stenting, left common iliac artery stenting, superior mesenteric artery stenting and renovascular disease. She had undergone multiple prior bilateral renal artery revascularization procedures as outlined below: At the current admission her blood pressure was elevated, with measurements ranging from 170 to 220/100 to 110 mmHg. Laboratory studies revealed that her estimated glomerular filtration rate (GFR) had attenuated to approximately 26 ml/min per 1.73 m 2 (from a baseline of greater than 60 ml/min per 1.73 m 2 approximately 6 months earlier) as her serum creatinine rose from 0.9 mg/dl to approximately 2.0 mg/dl. It was noted that from the time of her last renal artery endovascular procedure (August 2006) to her current admission (April 2007), the patient had not undergone further endovascular procedures or surgery. In addition, her CABG and aortic valve surgery had been performed prior to 2005. Therefore, further procedures did not play any significant role in adversely affecting her renal function at this time.
A renal duplex ultrasound on admission revealed a left renal artery peak systolic velocity (PSV) of 395 cm/s, renal to aortic ratio (RAR) of 5.8 and renal span of 10.3 cm. The right renal artery PSV was 520 cm/s, RAR was 7.9 and left renal span was 10.2 cm.
Given the presence of significant bilateral RAS in the setting of resistant hypertension and worsening renal insufficiency it was decided to percutaneously repair the RAS in a patient who was a poor surgical candidate (because of other co-morbid medical conditions).
Abdominal aortography and non-selective renal artery angiography were performed and confirmed bilateral renal artery in-stent restenosis. The right renal artery origin was engaged via the 'no touch' technique. 9 Selective angiography of the right renal artery was performed and revealed 95% in-stent restenosis of the proximal right renal artery stents. A 4-Fr catheter was transitioned into the renal artery distal to the lesion. A significant translesional pressure gradient of 40 mmHg was detected, confirming obstructive stenosis. Angioplasty was performed on the right renal artery using a 3.5 × 20 mm cutting balloon deployed at 12 atmospheres (atm). A repeat angiogram revealed residual stenosis of 40-70%. Intravascular ultrasound (IVUS) of the renal artery confirmed the continued presence of significant IRAS. Therefore, a 5.0 × 18 mm JOSTENT Graftmaster stent (Abbott, Abbott Park, IL, USA) was deployed. The stent was post-dilated using a 5.50 mm non-compliant balloon. Owing to stent and vessel recoil, at the ostium of the renal artery, further post-dilation was performed using a 6.0 mm Viatrac (Abbott) noncompliant balloon. This balloon was deployed at low inflation pressure in order to dilate the ostium to approximately 5.50 mm (as per compliance chart for the balloon). It was noted that the instructions for use suggested that JOSTENT Graftmaster stents have a maximum expansion diameter of 5.50 mm. Final angiography revealed a reduction in stenosis from 95% to 0-10%. Repeat IVUS revealed good stent apposition without evidence of dissection. Repeat hemodynamic assessment using a 4-Fr catheter revealed no further evidence of gradient.
The following day, intervention was performed on the left renal artery. After cannulation of the left renal artery (Figure 1 
Discussion
PTRAS is frequently performed to treat atherosclerotic RAS. Recent technical advances such as lower-profile devices, rapid exchange systems and improved anticoagulation agents 10 have combined to achieve a high technical success rate and a low procedural risk. Unfortunately, restenosis occurs in 6-23% of cases 8, 11 and remains the Achilles heel of this treatment modality. In contrast to the primary atherosclerotic stenosis, restenosis is usually caused by myointimal hyperplasia. 12 Predictors of restenosis following PTRAS include small vessel size (usually < 4.5 mm), length of stented segment, tobacco use and smoking, time to evaluation for restenosis, use of gold-coated stents, and bilateral renal artery disease. [14] [15] [16] [17] Restenosis is usually treated with PTRA or deployment of a second stent. 11 Bax et al. suggested that patients with stenosed renal artery stents can be treated successfully with PTRA in a majority of cases, with a success rate of 75% and stable renal function 1 year after repeated intervention. 11 Recurrent ISR, however, remains a significant problem for many patients. Creating a 'stent-sandwich', by placing a second stent within the original stent, stretches the wall of the artery and further stimulates myointimal hyperplasia, 17 leading to longterm failure of the stent and the necessity of repeated intervention. Consequently, research today has largely shifted to the prevention and management of restenosis. A variety of new techniques, many of which were originally aimed at treating in-stent restenosis in the coronary artery, are being used in conjunction with or in place of PTRAS to treat recurrent ISR.
CBA employs a balloon with microsurgical blades that deploy during inflation. The microsurgical blades can cut to the metal stent cage, which protects the arterial wall. 17, 18 The microblades provide several advantages over conventional PTRA: they anchor the balloon, disrupt the fibroelastic continuity of the neointimal hyperplasia, and induce a fault line for plaque. A study of CBA use in restenosed coronary arteries found CBA to be superior to standard angioplasty and roughly as effective as more expensive atheroablation. 19 CBA has shown promising results in the renal arteries as well, although no extensive studies have been conducted for renal use. Munneke et al. described a case in which a restenosed stent, which was unresponsive to PTRA, was successfully treated with CBA. 18 Similarly, Otah and Alhaddad described a case in which a severe restenosis subtotally occluding a renal artery was successfully treated with CBA after IVUS measurement of the vessel. 20 CBA effectiveness is currently limited by small size, stiffness, and bulk of available devices, and lack of efficacy in some cases. 18, 20 The use of endovascular brachytherapy in the renal arteries might offer another way to address restenosis. Radiation is delivered after PTRA through endovascular means at the site of the lesion to retard hyperplasia. 21 A study conducted by Williams et al. examined beta radiation brachytherapy in 15 patients with restenosed stents. They found only three restenosed stents in a mean 12-month follow-up. 22 Similar studies of gamma radiation brachytherapy conducted by Stoeteknuel-Friedli et al. and Waksman et al., each with 11 patients treated with brachytherapy, found that repeat treatment was necessary in only two and one patient respectively. 23, 24 However, no large or randomized studies have been conducted and general usage of brachytherapy is limited by lack of availability in the USA, as well as the high expense and necessary collaboration with several non-cardiology specialists. 17, 26 More recently, DES have shown promise in addressing high restenosis rates. Granillo et al. reported a case of complex bilateral RAS, involving the bifurcation, successfully treated with Paclitaxeleluting stents. 27 Similarly, Kakkar et al. reported a case of recurrent ISR patent 6 months after successful treatment with a DES. 28 At present, the efficacy of this therapy in renal arteries still lacks significant positive correlating data. As the renal vessels are generally larger than the coronary arteries, the current use of coronary DES in renal arteries is limited by the 4 mm maximum size of available stents. 26 Additionally, concerns have been raised over the durability of thinner coronary stents in the renal arteries. 28 The GREAT trial prospectively compared DES (low-profile Palmaz-Genesis peripheral stent) to bare metal stents (BMS) in the renal artery in a non-randomized prospective study. 29 This trial, however, failed to show an advantage for DES over BMS at 6 months of angiographic follow-up. Case reports have noted the potential use of atheroablative techniques in cases of recurrent RAS. One case of in-stent occlusion was crossed using an Excimer laser, then treated with CBA. 30 Another case uses rotational atherectomy to treat an ISR. 31 Although these techniques are used in coronary cases, their use in renal arteries is limited by large caliber and high rigidity. 18 In our particular case, the use of small diameter cutting balloons (4 mm) and 3.50 mm stents (post-dilated to 4.0 mm) may have resulted in small renal artery lumen size, thereby contributing to IRAS.
The use of polytetrafluoroethylene (PTFE)covered stents may offer a new and innovative way to treat recurrent RAS. Covered stents are designed to combine the effectiveness of surgical treatment with the minimal invasiveness of endovascular treatment. In reporting the results of a clinical trial of the Hemobahn-covered stent in cases of occlusive disease of the femoral and iliac arteries, Rubin and Sicard conclude that the results are as good as or superior to conventional stenting. 32 Often used in the treatment of aneurysms, dissection, and rupture, covered stents have also been used in cases of occlusive disease and ISR. A limited study of the feasibility of the Jostent peripheral stent-graft by Gaxotte et al. found it to be safe and effective in the treatment of each of the above pathologies in both renal and iliac arteries. 33 With this precedent, we present a complicated case of recurring ISR treated with a covered stent.
Current literature detailing Jostent peripheral stent-graft usage in renal arteries focuses on treatment of pseudoaneurysms, aneurysms and ruptures. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] To our knowledge, a trial published by Gaxotte et al. contains the only reported use of Jostents for ISR in a very small number of renal arteries and also iliac arteries. The JOSTENT stent-graft contains a layer of PTFE sandwiched between two stainless steel stents. As stent failure most often occurs via the growth of neointimal hyperplasia through the stent cage, the PTFE layer may retard this process by acting as a physical barrier. 30 Although, the PTFE covering does not prevent the hyperplasia in all cases, 39 it may be a plausible option with renal artery in-stent restenosis, as well as in de novo stenting for RAS. The PTFE covering may also prevent distal plaque emboli at the time of stenting ('cheese grating' effect with noncovered stents), and help to preserve renal function. In our case report, we suggest that the use of covered stents for IRAS appears promising in selective patients. At 12 months of follow-up there was no significant IRAS and no further deterioration of renal function or blood pressure control. However, implantation of covered stents for IRAS still requires further study in a randomized prospective trial.
